{"id":52256,"date":"2023-09-20T09:31:02","date_gmt":"2023-09-20T09:31:02","guid":{"rendered":"https:\/\/medsname.com\/hepcinat\/"},"modified":"2026-05-01T05:31:52","modified_gmt":"2026-05-01T05:31:52","slug":"hepcinat","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/hepcinat\/","title":{"rendered":"Hepcinat"},"content":{"rendered":"<div class=\"medsbase-tldr-answer\" style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<h3 style=\"margin-top:0;\">\u0393\u03c1\u03ae\u03b3\u03bf\u03c1\u03b7 \u03b1\u03c0\u03ac\u03bd\u03c4\u03b7\u03c3\u03b7<\/h3>\n<p style=\"margin-bottom:0;\"><strong>Hepcinat<\/strong> \u2014 sofosbuvir 400 mg (Natco Pharma). NS5B nucleotide polymerase inhibitor \u2014 backbone DAA for chronic hepatitis C, used in combination with NS5A inhibitors (daclatasvir, ledipasvir, velpatasvir) to achieve cure rates of 95-99%. Generic of Gilead Sovaldi.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f7f7f7;border-left:4px solid #2c7cb0;padding:14px 18px;margin:18px 0;border-radius:4px;\">\n<p style=\"margin:0 0 6px 0;\"><strong>\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong><\/p>\n<ul style=\"margin:6px 0 0 22px;padding:0;list-style:disc;\">\n<li>\u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf \u03b1\u03c0\u03cc \u03c4\u03b7 WHO-GMP \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae<\/li>\n<li>\u03a3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u03c3\u03b5 \u03b1\u03c0\u03bb\u03cc \u03c6\u03ac\u03ba\u03b5\u03bb\u03bf \u03c7\u03c9\u03c1\u03af\u03c2 \u03b5\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2<\/li>\n<li>\u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae<\/li>\n<li>\u0391\u03be\u03b9\u03bf\u03bb\u03bf\u03b3\u03ae\u03b8\u03b7\u03ba\u03b5 \u03b1\u03c0\u03cc 1,400+ \u03c0\u03b5\u03bb\u03ac\u03c4\u03b5\u03c2 (<a href=\"https:\/\/medsbase.com\/el\/reviews\/\">\u03b4\u03b9\u03b1\u03b2\u03ac\u03c3\u03c4\u03b5 \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2<\/a>)<\/li>\n<\/ul>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"background:#eef7ee;border-left:4px solid #4caf50;padding:10px 14px;margin:14px 0;border-radius:3px;\">\ud83d\udce6 <strong>\u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2:<\/strong> \u03b1\u03bd \u03b7 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03ad\u03c7\u03b5\u03b9 \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03bc\u03ad\u03c3\u03b1 \u03c3\u03b5 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03b5\u03c2 \u03b7\u03bc\u03ad\u03c1\u03b5\u03c2 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae, \u03c4\u03b7\u03bd \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5 \u03c7\u03c9\u03c1\u03af\u03c2 \u03c0\u03c1\u03cc\u03c3\u03b8\u03b5\u03c4\u03bf \u03ba\u03cc\u03c3\u03c4\u03bf\u03c2. <a href=\"https:\/\/medsbase.com\/el\/medsbase-re-shipment-assurance-policy\/\">\u0394\u03b9\u03b1\u03b2\u03ac\u03c3\u03c4\u03b5 \u03c4\u03b7\u03bd \u03c0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae<\/a>.<\/p>\n<h3>\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n<p>Hepcinat ships from a WHO-GMP certified manufacturer in plain packaging, billed through a regulated payment processor (the statement descriptor reads a regulated card-payment processor \u2014 never MedsBase or any medication name). Every order carries our 20-business-day Reshipment Assurance.<\/p>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:14px 0;border-radius:3px;\"><strong>FDA black-box: HBV reactivation<\/strong><br \/>All DAA Hep C therapies carry an FDA black-box warning for hepatitis B virus reactivation in patients co-infected with HCV + HBV (which can be fulminant and fatal). Test for HBsAg and HBV DNA before starting any DAA regimen. If HBV-positive, hepatology must manage co-treatment or prophylactic anti-HBV therapy.<\/div>\n<h2>How sofosbuvir works<\/h2>\n<p>Sofosbuvir is a uridine-nucleotide prodrug. Inside hepatocytes it is phosphorylated to its active triphosphate form, which is incorporated by the HCV NS5B RNA-dependent RNA polymerase into the growing viral RNA chain. Once incorporated it acts as a chain terminator \u2014 viral replication halts. Sofosbuvir is pan-genotypic and has a high barrier to resistance.<\/p>\n<p>Sofosbuvir is rarely used alone \u2014 it is the backbone of every modern HCV combination regimen. Common partners: daclatasvir (Natdac\/Mydekla\/Daclahep\/Hepcdac), ledipasvir (in fixed combinations Hepcvir L \/ Ledifos \/ MyHep LVIR), velpatasvir (in fixed combinations Velasof \/ Velpanat \/ Hepcvel \/ MyHep All).<\/p>\n<h2>Treatment-duration table<\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:12px 0;\">\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:8px;border:1px solid #ddd;\">Population<\/th>\n<th style=\"padding:8px;border:1px solid #ddd;\">\u03a0\u03c1\u03cc\u03b3\u03c1\u03b1\u03bc\u03bc\u03b1 \u03b8\u03b5\u03c1\u03b1\u03c0\u03b5\u03af\u03b1\u03c2<\/th>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;\">Genotype 1 \/ 4 \/ 5 \/ 6, treatment-naive, no cirrhosis<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">12 weeks (typically combined with NS5A inhibitor)<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border:1px solid #ddd;\">Genotype 2, no cirrhosis<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">12 weeks (sofosbuvir + ribavirin or sofosbuvir + daclatasvir)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;\">Genotype 3, no cirrhosis<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">12 weeks sofosbuvir + daclatasvir (sofosbuvir + velpatasvir is pan-genotypic alternative)<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border:1px solid #ddd;\">Compensated cirrhosis (any genotype)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">12 weeks combination DAA + ribavirin in selected cases; 24 weeks if treatment-experienced<\/td>\n<\/tr>\n<\/table>\n<p>Sustained virologic response at 12 weeks post-treatment (SVR12) is the marker of cure \u2014 achieved in ~95-99% of patients across modern DAA regimens.<\/p>\n<h2>\u03a3\u03b7\u03bc\u03b1\u03bd\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c6\u03b1\u03c1\u03bc\u03b1\u03ba\u03b5\u03c5\u03c4\u03b9\u03ba\u03ad\u03c2 \u03b1\u03bb\u03bb\u03b7\u03bb\u03b5\u03c0\u03b9\u03b4\u03c1\u03ac\u03c3\u03b5\u03b9\u03c2<\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:12px 0;\">\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:8px;border:1px solid #ddd;\">\u03a6\u03ac\u03c1\u03bc\u03b1\u03ba\u03bf<\/th>\n<th style=\"padding:8px;border:1px solid #ddd;\">Effect &amp; action<\/th>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;\">Amiodarone + sofosbuvir<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\"><strong>FDA warning \u2014 symptomatic bradycardia, deaths reported.<\/strong> Avoid combination. If unavoidable, in-hospital cardiac monitoring required.<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border:1px solid #ddd;\">PPIs (omeprazole, pantoprazole)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Reduce ledipasvir absorption (pH-dependent). Take ledipasvir-containing regimens with food and PPIs \u22654 hours apart, or use H2 blockers\/antacids instead. Velpatasvir also pH-sensitive \u2014 same advice.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;\">Rifampicin, rifabutin<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Strong CYP3A4 + P-gp inducers \u2014 significantly reduce DAA levels. Avoid combination.<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border:1px solid #ddd;\">\u0392\u03ac\u03bb\u03c3\u03b1\u03bc\u03bf \u03c4\u03bf\u03c5 \u0391\u03b3\u03af\u03bf\u03c5 \u0399\u03c9\u03ac\u03bd\u03bd\u03b7<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">CYP3A4 induction \u2014 reduces DAA levels and risks treatment failure. Avoid throughout therapy.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;\">Phenytoin, carbamazepine, oxcarbazepine<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Anticonvulsant inducers \u2014 significantly reduce DAA levels. Switch to non-inducing antiepileptic (lamotrigine, levetiracetam) before starting Hep C therapy.<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border:1px solid #ddd;\">Statins (rosuvastatin, atorvastatin)<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Variable rises in statin levels. Use lowest dose; rosuvastatin generally avoided with sof+vel; atorvastatin acceptable at low dose.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:8px;border:1px solid #ddd;\">\u0392\u03b1\u03c1\u03c6\u03b1\u03c1\u03af\u03bd\u03b7<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">INR can fluctuate as the liver recovers during DAA therapy. Monitor INR weekly until stable.<\/td>\n<\/tr>\n<tr style=\"background:#f9f9f9;\">\n<td style=\"padding:8px;border:1px solid #ddd;\">HIV antiretrovirals<\/td>\n<td style=\"padding:8px;border:1px solid #ddd;\">Tenofovir + ledipasvir \u2014 increased tenofovir exposure; monitor renal function. Efavirenz reduces velpatasvir levels \u2014 avoid combination. HCV-HIV co-infection always needs ID\/hepatology specialist input.<\/td>\n<\/tr>\n<\/table>\n<h2 id=\"faqs\">\u03a3\u03c5\u03c7\u03bd\u03ad\u03c2 \u0395\u03c1\u03c9\u03c4\u03ae\u03c3\u03b5\u03b9\u03c2<\/h2>\n<h3>What is the cure rate?<\/h3>\n<p>Modern DAA regimens achieve sustained virologic response (SVR12) \u2014 undetectable HCV RNA at 12 weeks post-treatment, considered cure \u2014 in 95-99% of patients across genotypes. Cirrhosis, prior treatment failure, and HCV\/HIV co-infection slightly reduce response rates.<\/p>\n<h3>What is SVR12?<\/h3>\n<p>Sustained Virologic Response at 12 weeks post-treatment. After completing a 12-week DAA course, HCV RNA is checked at 12 weeks after the last dose. Undetectable = cure. Late relapse beyond SVR12 is &lt;1%.<\/p>\n<h3>Will I need a follow-up test?<\/h3>\n<p>Yes. HCV RNA at the end of treatment + at 12 weeks post-treatment confirms SVR12. Liver biochemistry and FibroScan\/imaging at 6-12 months in cirrhotic patients to assess regression. Even after cure, screen for hepatocellular carcinoma every 6 months if cirrhosis is established.<\/p>\n<h3>What about hepatitis B?<\/h3>\n<p>All DAAs carry an FDA black-box warning for HBV reactivation in HCV+HBV co-infected patients. Test HBsAg and HBV DNA before starting. If HBV-positive, hepatology must coordinate.<\/p>\n<h3>\u039c\u03c0\u03bf\u03c1\u03ce \u03bd\u03b1 \u03c0\u03af\u03bd\u03c9 \u03b1\u03bb\u03ba\u03bf\u03cc\u03bb;<\/h3>\n<p>Avoid alcohol throughout treatment and ideally for 6-12 months after. Active alcohol use does not preclude DAA therapy but worsens long-term liver outcomes regardless of HCV status.<\/p>\n<h3>\u0395\u03b3\u03ba\u03c5\u03bc\u03bf\u03c3\u03cd\u03bd\u03b7;<\/h3>\n<p>Sofosbuvir is FDA pregnancy category B (no human teratogenicity data; animal data reassuring). Most DAAs lack pregnancy data. Contraception during therapy is standard. Ribavirin (where used as adjunct) is strongly teratogenic \u2014 both partners must use contraception during ribavirin therapy and 6 months after.<\/p>\n<h3>\u03a0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2;<\/h3>\n<p>Modern DAAs are generally well tolerated. Common: fatigue, headache, nausea, insomnia. Less common: rash, diarrhoea. Treatment-limiting side effects are rare.<\/p>\n<h3>Generic vs branded \u2014 does it matter?<\/h3>\n<p>Indian generic DAAs are manufactured under voluntary licences from Gilead (Sovaldi, Harvoni, Epclusa), AbbVie, and BMS. They are bioequivalent and have the same molecule. Multiple real-world studies (CT2, Plus-Asia) show equivalent SVR12 rates to branded products.<\/p>\n<h3>Drug interactions to watch?<\/h3>\n<p>Most important: amiodarone + sofosbuvir (bradycardia black-box), rifampicin (kills DAA levels), PPIs (reduce ledipasvir\/velpatasvir), HIV ARV adjustments needed in co-infection. Always disclose all medications including herbal\/OTC.<\/p>\n<h3>After cure \u2014 can I get HCV again?<\/h3>\n<p>Yes. SVR clears the current infection but does not provide future immunity. Re-infection through new exposures (IV drug use, unsafe medical procedures, MSM with HIV co-infection) is possible. Counsel on prevention and offer HCV RNA testing at any new risk exposure.<\/p>\n<p class=\"medsbase-link-boost-2026-04-30\" data-marker=\"mb-link-boost-hepcinat-lp\">Sofosbuvir is rarely used as monotherapy in modern Hep C protocols \u2014 for chronic HCV genotype 1, 4, 5, or 6 the standard regimen pairs sofosbuvir with ledipasvir as a single fixed-dose combination, available as <a href='\/el\/hepcinat-lp\/'>Hepcinat LP (sofosbuvir 400 mg + ledipasvir 90 mg)<\/a>.<\/p>\n<p data-mb-link-target=\"hepcinat-lp\" data-mb-anchor-variant=\"v2\" style=\"margin-top:1em;font-size:0.95em;color:#444;border-left:3px solid #2c7cb0;padding:0.5em 0.75em;background:#f4f8fb;\"><strong>\u0394\u03b5\u03af\u03c4\u03b5 \u03b5\u03c0\u03af\u03c3\u03b7\u03c2:<\/strong> <a href=\"https:\/\/medsbase.com\/el\/hepcinat-lp\/\"><strong>Hepcinat LP (sofosbuvir + ledipasvir)<\/strong><\/a> \u2014 Natco&#8217;s generic Harvoni \u2014 sofosbuvir 400 mg + ledipasvir 90 mg in a single 12-week course for hepatitis C genotypes 1, 4, 5, 6.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2>Other Hepatitis C Medications<\/h2>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/el\/natdac\/\">Natdac<\/a> \u2014 daclatasvir 30\/60 mg \u2014 pan-genotypic NS5A partner for sofosbuvir<\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/velpanat\/\">Velpanat<\/a> \u2014 sofosbuvir + velpatasvir fixed combination \u2014 pan-genotypic single-tablet<\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/ledifos\/\">Ledifos<\/a> \u2014 sofosbuvir + ledipasvir fixed combination \u2014 for genotypes 1, 4, 5, 6<\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/hepcvel\/\">Hepcvel<\/a> \u2014 sofosbuvir + velpatasvir \u2014 Cipla brand<\/li>\n<li><a href=\"https:\/\/medsbase.com\/el\/myhep-all\/\">MyHep All<\/a> \u2014 sofosbuvir + velpatasvir \u2014 Mylan brand<\/li>\n<\/ul>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:12px 16px;margin:18px 0;border-radius:3px;font-size:.95em;\"><strong>\u0399\u03b1\u03c4\u03c1\u03b9\u03ba\u03ae \u0391\u03c0\u03bf\u03c0\u03bf\u03af\u03b7\u03c3\u03b7 \u0395\u03c5\u03b8\u03c5\u03bd\u03ce\u03bd:<\/strong> \u0391\u03c5\u03c4\u03ae \u03b7 \u03c3\u03b5\u03bb\u03af\u03b4\u03b1 \u03c0\u03b1\u03c1\u03ad\u03c7\u03b5\u03b9 \u03bc\u03cc\u03bd\u03bf \u03c0\u03bb\u03b7\u03c1\u03bf\u03c6\u03bf\u03c1\u03af\u03b5\u03c2 \u03ba\u03b1\u03b9 \u03b4\u03b5\u03bd \u03b1\u03c0\u03bf\u03c4\u03b5\u03bb\u03b5\u03af \u03c5\u03c0\u03bf\u03ba\u03b1\u03c4\u03ac\u03c3\u03c4\u03b1\u03c4\u03bf \u03b9\u03b1\u03c4\u03c1\u03b9\u03ba\u03ae\u03c2 \u03c3\u03c5\u03bc\u03b2\u03bf\u03c5\u03bb\u03ae\u03c2 \u03b1\u03c0\u03cc \u03b5\u03b9\u03b4\u03b9\u03ba\u03cc. \u03a3\u03c5\u03b6\u03b7\u03c4\u03ae\u03c3\u03c4\u03b5 \u03ba\u03ac\u03b8\u03b5 \u03bd\u03ad\u03bf \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03bf \u03bc\u03b5 \u03c4\u03bf\u03bd \u03b3\u03b9\u03b1\u03c4\u03c1\u03cc \u03ae \u03c4\u03bf\u03bd \u03c6\u03b1\u03c1\u03bc\u03b1\u03ba\u03bf\u03c0\u03bf\u03b9\u03cc \u03c3\u03b1\u03c2.<\/div>","protected":false},"excerpt":{"rendered":"<p>Hepcinat (Sofosbuvir 400 mg) \u2014 Natco generic of Sovaldi. Pan-genotypic NS5B chain-terminator backbone for HCV; partnered with NS5A inhibitor for 12-week treatment.<\/p>","protected":false},"featured_media":52257,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3141,3223,3334],"product_tag":[],"class_list":{"0":"post-52256","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-category-overview","7":"product_cat-chronic-conditions","8":"product_cat-hepatitis-medication","10":"first","11":"outofstock","12":"shipping-taxable","13":"purchasable","14":"product-type-variable","15":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product\/52256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/comments?post=52256"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media\/52257"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/media?parent=52256"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_brand?post=52256"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_cat?post=52256"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/el\/wp-json\/wp\/v2\/product_tag?post=52256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}